Replies to post #1418 on Entremed (ENMD)

[marcpw]

re "Still curious as to whether a single corporation/person/group/ institution was responsible for last week's volume spike up, since there was no published clinical or transactional news, and there were some fairly large blocks."

Just from looking at daily charts at the time it seemed there were about 200K shares blocks purchased after the opening on Fri and Mon a week ago ago at about $2 and $2.50 per share respectively. Besides that apparent $1 Million purchase by some entity the rest seemed to be a lot of daytrader noise. With daytrader distortion of volume in every hot moving stock I think total volume gets exaggerated in terms of meaning. Now who made those apparent two big buys at around $2 and $2.50 is a matter of speculation

[C_Peptide]

re: can aspirin be far behind?

Nottadoc2, I know you're just kidding here. Fortunately, the cardiovascular benefits of aspirin are well-established in large trials. Aspirin has probably prevented more heart attacks than any other single drug, due mainly to its ability to permanently disable platelets. The naproxen findings are preliminary and surprising. I think the media is getting a little carried away.

While the reporting and the political machinations surrounding the cardiovascular risks of various NSAIDS is giving off more heat than light, there may be one benefit. Hopefully, the heightened drug safety concerns will serve to moderate the attitude that decades of sedentary gluttony, consuming sugar-frosted trans-fat bombs can or should be counteracted with a pill, and maybe a healthy, moderate diet, vitamins and exercise is a better way to go.

Best Regards,
C-Peptide